Bone cancer treatment ineffective, despite promising laboratory data

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult. A new study published in Pediatric Blood & Cancer evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news145558218.html">Bone cancer treatment ineffective, despite promising laboratory data</a></p> <p>Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult. A new study published in <I>Pediatric Blood & Cancer</I> evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.</p>